Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: TTfinancial who wrote (12683)	3/2/1999 8:47:00 AM
From: dexx	Respond to of 25711

DMRX is waking up. Info below from new DMRX thread: DermaRx Corporation (OTCBB: DMRX) 284 S. Jackson St. Denver, CO 80206 (303) 333-4600 Pres. & CEO: Maryanne Carroll VP: Gerit Mulder Outstanding Shares: 9.87 million Float: Approximately 3 million Brief Overview of Company: DMRX works through its two wholly owned subsidiaries Dermedics and Wound Sciences, Inc. Dermedics manufactures and markets numerous products including HemorRx, BottomBetter, PsoRxin, DermaMed Cleanser and GeriMend Skin Therapy. Wound Sciences, Inc. provides wound protocol development for hospitals and nursing homes. A clinical evaluation of HemorRx was recently completed with very favorable results. 98% of the patients experienced sympton relief within 3 days. As a result, DMRX has entered into a distribution agreement with a drug store chain, RXPlus. I like what I see so far. My research shows that a little over a year ago this stock was trading at $1.00.